Ropinirole approved for restless legs

GlaxoSmithKline has gained approval for its dopamine agonist ropinirole to be used for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome.

GlaxoSmithKline currently markets ropinirole for the treatment of Parkinson's disease under the brand name of Requip, but to distinguish between the two indications ropinirole will also be marketed as Adartrel for restless legs syndrome.

The recommended starting dose for patients with restless legs syndrome is 0.25mg once daily at bedtime for two days. If well tolerated, the dose may be increased to 0.5mg once daily for the rest of the first week, then subsequently by 0.5mg per week to the average dose of 2mg once daily. Some patients may benefit from a further gradual increase to a maximum of 4mg once daily.

Adartrel is available as film-coated tablets containing ropinirole 0.25mg, 0.5mg or 2mg.

Further information: GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT. Tel: (0800) 221441.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more